CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 62 enrolled
Drug / intervention
Dalteparin Sodiumdrug
Likely dose
Dalteparin Sodium 5,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01274637
NCT01274637Phase 3Completed
CompareCT.gov

Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism

Ottawa Hospital Research Institute·interventional·Posted Jan 11, 2011·Updated Aug 1, 2017

In Brief

A Phase 3 clinical trial evaluating Dalteparin Sodium for Venous Thromboembolism and Postpartum. Completed, enrolled 62 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism, Postpartum
CountriesCanada, United States
CollaboratorsCanadian Institutes of Health Research (CIHR)

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2011
Enrollment StartMar 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.5 years ago

Interventions

Dalteparin Sodiumdrug

5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.